V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10412394 | 10064925 | 1.68 | 66 | Neo-adjuvant (N) | 2017-08-02 | 2017-12-21 | null | 2 | N | CYTARABINE | 100190269 |
| 10412690 | 10064926 | null | null | null | 2021-06-29 | 2022-01-01 | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE + RITUXIMAB | null | null | CYTARABINE | 100651306 |
| 10412812 | 10064928 | 1.77 | 89.8 | null | null | 2017-11-14 | Carboplatin + Pembrolizumab + Pemetrexed | Y | null | CAPECITABINE + MITOMYCIN | 100664219 |
| 10413092 | 10064929 | null | null | null | 2014-10-14 | 2018-11-23 | GEMTUZUMAB OZOGAMICIN | 02 | null | OBINUTUZUMAB + VENETOCLAX | 100338791 |
| 10413115 | 10064930 | 1.68 | 80.4 | null | 2017-11-18 | 2017-12-06 | ESHAP R | 2 | null | TRASTUZUMAB EMTANSINE | 100287870 |
| 10413781 | 10064935 | 1.68 | 77 | Adjuvant (A) | 2019-12-27 | 2020-01-01 | VISMODEGIB | 02 | N | OFATUMUMAB | 100236851 |
| 10414044 | 10064938 | 1.73 | 82.4 | null | 2017-12-07 | 2018-01-04 | GEMCITABINE + OXALIPLATIN + RITUXIMAB | 02 | null | LOMUSTINE | 101077913 |
| 10414088 | 10064939 | 1.82 | 81 | null | 2019-07-17 | 2019-07-19 | null | 02 | null | BEVACIZUMAB | 101747330 |
| 10414161 | 10064940 | 1.63 | 64.45 | null | 2020-07-18 | 2020-07-19 | ISATUXIMAB + POMALIDOMIDE | 02 | null | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN + FLUOROURACIL | 100123637 |
| 10414433 | 10064941 | 1.8 | 66 | Curative (C) | 2018-05-10 | 2018-05-11 | Cetuximab + Oxaliplatin + MdG Maint | 02 | N | BEXAROTENE | 100008163 |
| 10415125 | 10064947 | 1.7 | 67.3 | Curative (C) | 2018-12-16 | 2018-12-30 | ISATUXIMAB + POMALIDOMIDE | 02 | N | CISPLATIN + FLUOROURACIL + RT | 101037935 |
| 10415757 | 10064948 | 1.72 | 69.8 | Palliative (P) | 2017-02-22 | 2017-03-06 | Gefitinib: 1 to 2 & 4 onwards | 02 | N | OBINUTUZUMAB | 100657848 |
| 10415900 | 10064949 | 0 | 53.5 | Curative (C) | 2020-02-07 | 2020-04-25 | THALIDOMIDE | 02 | N | STAMPEDE TRIAL | 101412971 |
| 10416056 | 10064951 | 1.69 | 67.5 | Neo-adjuvant (N) | 2012-08-17 | 2018-12-20 | Inotuzumab Ozogamicin | 02 | N | CYCLOPHOSPHAMIDE + RITUXIMAB | 101496031 |
| 10416063 | 10064952 | 1.68 | 75 | null | null | 2020-10-20 | null | 02 | null | TRANSPLANT ALEMTUZUMAB + FLUDARABINE + MELPHALAN | 101234752 |
| 10416414 | 10064954 | 1.55 | 72.55 | Palliative (P) | null | 2018-11-25 | Epirubicin | 02 | N | CLARITY TRIAL | 101065121 |
| 10416573 | 10064955 | 1.83 | 58 | null | 2018-04-23 | 2018-05-07 | INTERFERON | 02 | null | THALIDOMIDE | 101836152 |
| 10416647 | 10064956 | 1.69 | 89.8 | Palliative (P) | 2017-11-26 | 2018-02-16 | MYELOMA XI TRIAL | 02 | N | RUCAPARIB | 100367459 |
| 10417036 | 10064958 | 1.52 | 74.7 | null | 2016-03-12 | 2016-03-12 | LENALIDOMIDE + RITUXIMAB | 02 | null | ECX | 101532615 |
| 10417251 | 10064959 | 0 | 82 | null | 2019-01-30 | 2019-01-31 | Docetaxel + Nintedanib | null | null | GEMCITABINE + NAB-PACLITAXEL | 101112452 |
| 10417622 | 10064960 | 1.73 | 79 | null | 2020-05-01 | 2020-10-19 | null | 02 | null | PEG INTERFERON | 101605680 |
| 10417678 | 10064961 | 1.67 | 71.8 | Palliative (P) | 2017-12-01 | 2017-12-06 | null | 02 | N | NOT MATCHED | 100734630 |
| 10417777 | 10064962 | 1.66 | 89 | null | 2018-09-13 | 2018-10-02 | GEMCITABINE + OXALIPLATIN + RITUXIMAB | 02 | null | CYTARABINE + FLUDARABINE + IDARUBICIN | 100083001 |
| 10418182 | 10064963 | 1.67 | 50.6 | Curative (C) | 2018-12-16 | 2018-12-16 | FCR Oral - Cycle 2 onwards | 02 | N | CISPLATIN + GEMCITABINE + RITUXIMAB | 100395833 |
| 10418399 | 10064964 | 1.68 | 70.9 | null | null | 2021-09-30 | PEG INTERFERON | 02 | null | CYTARABINE + DAUNORUBICIN | 100748570 |
| 10418509 | 10064966 | 1.56 | 90.2 | Palliative (P) | 2018-03-24 | 2018-04-21 | Cisplatin + Pemetrexed | 02 | N | CYTARABINE | 101204312 |
| 10418578 | 10064968 | 1.82 | 66.7 | null | null | 2019-11-23 | Apalutamide | 02 | null | BEVACIZUMAB | 100713107 |
| 10418791 | 10064969 | 1.88 | 0 | 03 | 2017-10-22 | 2017-10-26 | Cetuximab + Encorafenib | 02 | N | LENVATINIB | 100005370 |
| 10419025 | 10064971 | 1.77 | 0 | null | 2012-11-16 | 2019-11-15 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | 02 | null | OXALIPLATIN + MDG | 100296097 |
| 10419090 | 10064972 | null | null | Adjuvant (A) | 2019-04-20 | 2020-01-12 | Irinotecan + Modified De Gramont | null | N | FLAIR TRIAL | 100035807 |
| 10419147 | 10064973 | 1.66 | 70 | 03 | 2019-06-01 | 2019-06-15 | CYCLOPHOSPHAMIDE + ETOPOSIDE + LOMUSTINE | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100712481 |
| 10419533 | 10064977 | 1.72 | 52.8 | Palliative (P) | 2019-02-24 | 2019-03-03 | Bortezomib + MELPHALAN | 02 | N | CYCLOPHOSPHAMIDE + GEMCITABINE + RITUXIMAB + VINCRISTINE | 100711038 |
| 10419608 | 10064978 | 1.74 | 103 | Palliative (P) | 2018-02-17 | 2018-02-17 | Pemetrexed | 02 | N | GEMCITABINE + OXALIPLATIN | 100265850 |
| 10419776 | 10064979 | 1.66 | 56 | null | null | 2021-07-22 | MPV (cycle 1-4) | 02 | null | LIPOSOMAL DOXORUBICIN | 100659154 |
| 10420420 | 10064980 | null | null | Curative (C) | 2019-09-09 | 2019-09-11 | Bendamustine + Obinutuzumab | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 101685822 |
| 10420614 | 10064982 | 1.88 | 56.7 | Curative (C) | 2016-10-23 | 2017-11-16 | CYCLOPHOSPHAMIDE + ETOPOSIDE + Procarbazine | 02 | N | CYCLOPHOSPHAMIDE + ETOPOSIDE + PROCARBAZINE | 101164902 |
| 10420727 | 10064983 | 1.58 | 70 | Palliative (P) | 2019-07-09 | 2019-09-04 | Cisplatin + Pemetrexed | 02 | N | IXAZOMIB | 100157235 |
| 10420873 | 10064985 | 1.67 | 47 | Palliative (P) | null | 2018-05-19 | Paclitaxel albumin (Abraxane) 21day | 02 | N | AML18 TRIAL | 100769892 |
| 10420884 | 10064986 | 1.82 | 54.6 | null | 2019-06-28 | 2019-08-25 | Dacarbazine | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 101818491 |
| 10420990 | 10064987 | 0 | 75.3 | Curative (C) | 2018-08-24 | 2018-10-02 | Cisplatin + Etoposide po&iv 3 day | 02 | null | FLAIR TRIAL | 100339899 |
| 10421080 | 10064989 | 1.75 | 50 | null | 2018-04-09 | 2018-04-09 | Abemaciclib | 02 | null | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 100973788 |
| 10421566 | 10064992 | 0 | 67.8 | Neo-adjuvant (N) | 2019-06-16 | 2019-06-16 | null | 02 | N | IDELALISIB | 100888438 |
| 10421926 | 10064996 | 0 | 80.9 | 03 | 2020-04-27 | 2020-04-27 | Carboplatin + Cetux + FU (Cycle 1) | 02 | N | IRINOTECAN + MDG | 101205507 |
| 10422194 | 10064997 | 1.78 | 62 | Palliative (P) | 2017-04-23 | 2017-05-14 | Ipilimumab | 02 | N | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | 100340854 |
| 10422305 | 10064999 | 0 | 72.6 | null | 2021-01-02 | 2021-01-11 | Midostaurin | N | N | TRASTUZUMAB DERUXTECAN | 100263951 |
| 10422449 | 10065000 | 1.5 | 77.5 | null | 2018-03-04 | 2019-06-25 | Cisplatin + Pemetrexed | 02 | null | DOXORUBICIN + OLARATUMAB | 100484608 |
| 10422545 | 10065001 | 1.8 | 76.2 | null | 2017-10-06 | 2017-12-07 | null | 02 | null | CISPLATIN + CYTARABINE + ETOPOSIDE | 101696199 |
| 10422815 | 10065003 | 1.84 | 85 | null | null | 2019-11-14 | Bortezomib + Panobinostat + Thalidomide | 02 | null | TOPOTECAN | 100798178 |
| 10423089 | 10065004 | 1.61 | 69 | null | 2019-11-16 | 2019-12-25 | Trial Unspecified | 02 | null | CHLORAMBUCIL + RITUXIMAB | 101646647 |
| 10423155 | 10065005 | null | null | 03 | 2018-03-28 | 2018-03-31 | GEMCITABINE + OXALIPLATIN + RITUXIMAB | 2 | N | CETUXIMAB + IRINOTECAN + MDG | 101394410 |